~ Minimum Follow-up in Trial Now Four
Years
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced
long-term follow-up data from the Phase 1 trial of Iclusig®
(ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated
patients with resistant or intolerant chronic myeloid leukemia
(CML) or Philadelphia chromosome-positive acute lymphoblastic
leukemia (Ph+ ALL). With a median follow-up of over four years
(53.1 months), Iclusig continues to demonstrate anti-leukemic
activity in chronic-phase (CP) CML patients with limited treatment
options (n=43). Overall, 72 percent of CP-CML patients achieved a
major cytogenetic response (MCyR) on trial, 65 percent a complete
cytogenetic response (CCyR) and 56 percent a major molecular
response (MMR). Long-term safety data on ponatinib indicate that
benefit-risk evaluations should guide decisions to initiate and
maintain therapy, particularly in patients who may be at increased
risk for arterial occlusive events.
These data are included in a poster presentation today at the
Annual Meeting of the American Society of Clinical Oncology taking
place in Chicago.
“With more than half of the CP-CML patients still on study after
a minimum of four years, ponatinib continues to maintain
anti-leukemic responses in this heavily pre-treated patient
population,” stated Moshe Talpaz, M.D., The Alexander J. Trotman
Professor of Leukemia Research, Associate Director of Translational
Research, Co-Director of Hematologic Malignancies/BMT Program at
the University of Michigan Comprehensive Cancer Center. “We are
continuing to study the profile of ponatinib and the impact of dose
reductions in patients with CML and Ph+ ALL for whom there are
limited treatment options and the potential benefit outweighs the
risk.”
Phase 1 Trial Long-Term Data
The Phase 1 dose-escalation study of ponatinib (dose range, 2 to
60 mg once daily) enrolled 81 patients with resistant or refractory
hematologic cancers, including 43 patients with CP-CML. Sixty
percent of CP-CML patients in this study had failed at least three
prior tyrosine kinase inhibitors (TKI), and 98 percent received at
least two prior TKIs. Twenty-two CP-CML patients (51 percent)
remain on study. Data presented at ASCO focus on CP-CML patients
and represent follow-up through February 2, 2015.
- Median follow-up for CP-CML patients is
over 4 years (53.1 months) with a maximum follow-up of six years
(69.9 months).
- Of 22 ongoing CP-CML patients, 14 are
receiving a dose of 15 mg/day ponatinib or less, 5 on 30 mg/day,
and 3 on 45 mg/day; the mean current dose is 22.5 mg/day. The
median dose intensity for these patients during the course of the
study was 33.7 mg/day.
- Anti-leukemic activity continues to be
observed with ponatinib treatment:
- 72 percent of CP-CML patients achieved
MCyR, 65 percent CCyR and 56 percent MMR. Of note, 77 percent
(17/22) of ongoing CP-CML patients are in deep molecular response
of MMR or better,
- The median times to MCyR, CCyR and MMR
were 2.8, 5.5 and 7.4 months, respectively.
- By Kaplan-Meier estimate, the
probability of CP-CML patients maintaining MCyR at 4 years was 71
percent.
- Ten of the 15 CP-CML patients (67%) who
started ponatinib at a dose of 30 mg or less achieved MCyR.
- Of the 12 CP-CML patients with the
T315I mutation enrolled in the trial, 1 discontinued; 10 of the 11
CP-CML patients with the T315I mutation who remained on study
achieved MCyR, with 8 of 10 in continuous MCyR.
- The most common treatment-emergent
adverse events (≥ 50%) occurring in CP-CML patients were rash
(65%), fatigue (63%), abdominal pain (58%), headache (58%),
arthralgia (53%), and constipation (51%).
- The most common serious
treatment-emergent adverse events were abdominal pain, atrial
fibrillation, myocardial infarction, and pancreatitis (n=4
each).
- Thirty percent (n=13) of CP-CML
patients experienced a serious arterial occlusive event (AOE); 40
percent (n=17) of CP-CML patients experienced an AOE of any
severity. Two patients experienced a venous thromboembolic event
(VTEs); no serious VTEs were observed. No patient death was
attributed to an AOE or VTE. No new AOEs have been reported since
study data were last reported in December 2014 (data as of
September 26, 2014).
“The long-term follow-up results from the Phase 1 study of
ponatinib in patients with chronic myeloid leukemia in the chronic
phase show that responding patients can achieve lasting, deep
responses,” said Frank G. Haluska, M.D., Ph.D., chief medical
officer and senior vice president, clinical R&D at ARIAD. “As
we expect to start enrolling patients into the randomized OPTIC
(Optimizing Ponatinib in CML)
dose-ranging study shortly, the observed robust response rates and
response durations support exploring lower doses in refractory
patients.”
About Iclusig® (ponatinib) tablets
Iclusig is approved in the U.S., EU, Switzerland, Australia,
Canada and Israel.
In the U.S., Iclusig is a kinase inhibitor indicated for
the:
• Treatment of adult patients with T315I-positive chronic
myeloid leukemia (chronic phase, accelerated phase, or blast phase)
or T315I-positive Philadelphia chromosome positive acute
lymphoblastic leukemia (Ph+ ALL).
•Treatment of adult patients with chronic phase, accelerated
phase, or blast phase chronic myeloid leukemia or Ph+ ALL for whom
no other tyrosine kinase inhibitor (TKI) therapy is indicated.
These indications are based upon response rate. There are no
trials verifying an improvement in disease-related symptoms or
increased survival with Iclusig.
IMPORTANT SAFETY INFORMATION, INCLUDING THE BOXED
WARNING
WARNING: VASCULAR OCCLUSION, HEART FAILURE, and
HEPATOTOXICITY
See full prescribing information for complete boxed
warning
- Vascular Occlusion: Arterial and
venous thrombosis and occlusions have occurred in at least 27% of
Iclusig treated patients, including fatal myocardial infarction,
stroke, stenosis of large arterial vessels of the brain, severe
peripheral vascular disease, and the need for urgent
revascularization procedures. Patients with and without
cardiovascular risk factors, including patients less than 50 years
old, experienced these events. Monitor for evidence of
thromboembolism and vascular occlusion. Interrupt or stop Iclusig
immediately for vascular occlusion. A benefit risk consideration
should guide a decision to restart Iclusig therapy.
- Heart Failure, including fatalities,
occurred in 8% of Iclusig-treated patients. Monitor cardiac
function. Interrupt or stop Iclusig for new or worsening heart
failure.
- Hepatotoxicity, liver failure and
death have occurred in Iclusig-treated patients. Monitor hepatic
function. Interrupt Iclusig if hepatotoxicity is
suspected.
Vascular Occlusion: Arterial and venous thrombosis and
occlusions, including fatal myocardial infarction, stroke, stenosis
of large arterial vessels of the brain, severe peripheral vascular
disease, and the need for urgent revascularization procedures have
occurred in at least 27% of Iclusig-treated patients from the phase
1 and phase 2 trials. Iclusig can also cause recurrent or
multi-site vascular occlusion. Overall, 20% of Iclusig-treated
patients experienced an arterial occlusion and thrombosis event of
any grade. Fatal and life-threatening vascular occlusion has
occurred within 2 weeks of starting Iclusig treatment and in
patients treated with average daily dose intensities as low as 15
mg per day. The median time to onset of the first vascular
occlusion event was 5 months. Patients with and without
cardiovascular risk factors have experienced vascular occlusion
although these events were more frequent with increasing age and in
patients with prior history of ischemia, hypertension, diabetes, or
hyperlipidemia. Interrupt or stop Iclusig immediately in patients
who develop vascular occlusion events.
Heart Failure: Fatal and serious heart failure or left
ventricular dysfunction occurred in 5% of Iclusig-treated patients
(22/449). Eight percent of patients (35/449) experienced any grade
of heart failure or left ventricular dysfunction. Monitor patients
for signs or symptoms consistent with heart failure and treat as
clinically indicated, including interruption of Iclusig. Consider
discontinuation of Iclusig in patients who develop serious heart
failure.
Hepatotoxicity: Iclusig can cause hepatotoxicity,
including liver failure and death. Fulminant hepatic failure
leading to death occurred in an Iclusig-treated patient within one
week of starting Iclusig. Two additional fatal cases of acute liver
failure also occurred. The fatal cases occurred in patients with
blast phase CML (BP-CML) or Philadelphia chromosome positive acute
lymphoblastic leukemia (Ph+ ALL). Severe hepatotoxicity occurred in
all disease cohorts. Iclusig treatment may result in elevation in
ALT, AST, or both. Monitor liver function tests at baseline, then
at least monthly or as clinically indicated. Interrupt, reduce or
discontinue Iclusig as clinically indicated.
Hypertension: Treatment-emergent hypertension (defined as
systolic BP≥140 mm Hg or diastolic BP≥90 mm Hg on at least one
occasion) occurred in 67% of patients (300/449). Eight patients
treated with Iclusig (2%) experienced treatment-emergent
symptomatic hypertension as a serious adverse reaction, including
one patient (<1%) with hypertensive crisis. Patients may require
urgent clinical intervention for hypertension associated with
confusion, headache, chest pain, or shortness of breath. In 131
patients with Stage 1 hypertension at baseline, 61% (80/131)
developed Stage 2 hypertension. Monitor and manage blood pressure
elevations during Iclusig use and treat hypertension to normalize
blood pressure. Interrupt, dose reduce, or stop Iclusig if
hypertension is not medically controlled.
Pancreatitis: Clinical pancreatitis occurred in 6%
(28/449) of patients (5% Grade 3) treated with Iclusig.
Pancreatitis resulted in discontinuation or treatment interruption
in 6% of patients (25/449). The incidence of treatment-emergent
lipase elevation was 41%. Check serum lipase every 2 weeks for the
first 2 months and then monthly thereafter or as clinically
indicated. Consider additional serum lipase monitoring in patients
with a history of pancreatitis or alcohol abuse. Dose interruption
or reduction may be required. In cases where lipase elevations are
accompanied by abdominal symptoms, interrupt treatment with Iclusig
and evaluate patients for pancreatitis. Do not consider restarting
Iclusig until patients have complete resolution of symptoms and
lipase levels are less than 1.5 x ULN.
Neuropathy: Peripheral and cranial neuropathy have
occurred in Iclusig-treated patients. Overall, 13% (59/449) of
Iclusig-treated patients experienced a peripheral neuropathy event
of any grade (2%, grade 3/4). In clinical trials, the most common
peripheral neuropathies reported were peripheral neuropathy (4%,
18/449), paresthesia (4%, 17/449), hypoesthesia (2%, 11/449), and
hyperesthesia (1%, 5/449). Cranial neuropathy developed in 1%
(6/449) of Iclusig-treated patients (<1% grade 3/4). Of the
patients who developed neuropathy, 31% (20/65) developed neuropathy
during the first month of treatment. Monitor patients for symptoms
of neuropathy, such as hypoesthesia, hyperesthesia, paresthesia,
discomfort, a burning sensation, neuropathic pain or weakness.
Consider interrupting Iclusig and evaluate if neuropathy is
suspected.
Ocular Toxicity: Serious ocular toxicities leading to
blindness or blurred vision have occurred in Iclusig-treated
patients. Retinal toxicities including macular edema, retinal vein
occlusion, and retinal hemorrhage occurred in 3% of Iclusig-treated
patients. Conjunctival or corneal irritation, dry eye, or eye pain
occurred in 13% of patients. Visual blurring occurred in 6% of the
patients. Other ocular toxicities include cataracts, glaucoma,
iritis, iridocyclitis, and ulcerative keratitis. Conduct
comprehensive eye exams at baseline and periodically during
treatment.
Hemorrhage: Serious bleeding events, including
fatalities, occurred in 5% (22/449) of patients treated with
Iclusig. Hemorrhagic events occurred in 24% of patients. The
incidence of serious bleeding events was higher in patients with
accelerated phase CML (AP-CML), BP-CML, and Ph+ ALL. Most
hemorrhagic events, but not all occurred in patients with grade 4
thrombocytopenia. Interrupt Iclusig for serious or severe
hemorrhage and evaluate.
Fluid Retention: Serious fluid retention events occurred
in 3% (13/449) of patients treated with Iclusig. One instance of
brain edema was fatal. In total, fluid retention occurred in 23% of
the patients. The most common fluid retention events were
peripheral edema (16%), pleural effusion (7%), and pericardial
effusion (3%). Monitor patients for fluid retention and manage
patients as clinically indicated. Interrupt, reduce, or discontinue
Iclusig as clinically indicated.
Cardiac Arrhythmias: Symptomatic bradyarrhythmias that
led to a requirement for pacemaker implantation occurred in 1%
(3/449) of Iclusig-treated patients. Advise patients to report
signs and symptoms suggestive of slow heart rate (fainting,
dizziness, or chest pain). Supraventricular tachyarrhythmias
occurred in 5% (25/449) of Iclusig-treated patients. Atrial
fibrillation was the most common supraventricular tachyarrhythmia
and occurred in 20 patients. For 13 patients, the event led to
hospitalization. Advise patients to report signs and symptoms of
rapid heart rate (palpitations, dizziness). Interrupt Iclusig and
evaluate.
Myelosuppression: Severe (grade 3 or 4) myelosuppression
occurred in 48% (215/449) of patients treated with Iclusig. The
incidence of these events was greater in patients with AP-CML,
BP-CML and Ph+ ALL than in patients with CP-CML. Obtain complete
blood counts every 2 weeks for the first 3 months and then monthly
or as clinically indicated, and adjust the dose as recommended.
Tumor Lysis Syndrome: Two patients (<1%) with advanced
disease (AP-CML, BP-CML, or Ph+ ALL) treated with Iclusig developed
serious tumor lysis syndrome. Hyperuricemia occurred in 7% (30/449)
of patients overall; the majority had CP-CML (19 patients). Due to
the potential for tumor lysis syndrome in patients with advanced
disease, ensure adequate hydration and treat high uric acid levels
prior to initiating therapy with Iclusig.
Compromised Wound Healing and Gastrointestinal
Perforation: Since Iclusig may compromise wound healing,
interrupt Iclusig for at least 1 week prior to major surgery.
Serious gastrointestinal perforation (fistula) occurred in one
patient 38 days post-cholecystectomy.
Embryo-Fetal Toxicity: Iclusig can cause fetal harm. If
Iclusig is used during pregnancy, or if the patient becomes
pregnant while taking Iclusig, the patient should be apprised of
the potential hazard to the fetus. Advise women to avoid pregnancy
while taking Iclusig.
Most common non-hematologic adverse reactions: (≥20%)
were hypertension, rash, abdominal pain, fatigue, headache, dry
skin, constipation, arthralgia, nausea, and pyrexia. Hematologic
adverse reactions included thrombocytopenia, anemia, neutropenia,
lymphopenia, and leukopenia.
Please see the full U.S. Prescribing Information for
Iclusig, including the Boxed Warning, for additional important
safety information.
About ARIAD
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge,
Massachusetts and Lausanne, Switzerland, is an integrated global
oncology company focused on transforming the lives of cancer
patients with breakthrough medicines. ARIAD is working on new
medicines to advance the treatment of various forms of chronic and
acute leukemia, lung cancer and other difficult-to-treat cancers.
ARIAD utilizes computational and structural approaches to design
small-molecule drugs that overcome resistance to existing cancer
medicines. For additional information, visit
http://www.ariad.com or follow ARIAD on Twitter
(@ARIADPharm).
Forward-Looking Statements
This press release contains forward-looking statements, each of
which are qualified in their entirety by this cautionary statement.
Any statements contained herein which do not describe historical
facts, including, but not limited to, statements related to:
updated clinical data for Iclusig; the therapeutic potential of
Iclusig and the expected timing for starting to enroll patients in
our OPTIC dose-ranging study, are forward-looking statements that
are based on management's expectations and are subject to certain
factors, risks and uncertainties that may cause actual results,
outcome of events, timing and performance to differ materially from
those expressed or implied by such statements. These factors, risks
and uncertainties include, but are not limited to: early-stage
clinical data may not be replicated in later-stage clinical
studies, the costs associated with our research, development,
manufacturing and other activities, the conduct, timing and results
of pre-clinical and clinical studies of Iclusig and our product
candidates, the adequacy of our capital resources and the
availability of additional funding; safety issues related to
Iclusig and those additional factors detailed in our public filings
with the U.S. Securities and Exchange Commission, including our
most recent Annual Report on Form 10-K and subsequent Quarterly
Reports on Form 10-Q. Except as otherwise noted, these
forward-looking statements speak only as of the date of this press
release and we undertake no obligation to update or revise any of
these statements to reflect events or circumstances occurring after
this press release. We caution investors not to place considerable
reliance on the forward-looking statements contained in this press
release.
Iclusig® is a registered trademark of ARIAD Pharmaceuticals,
Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150531005022/en/
ARIAD Pharmaceuticals, Inc.For InvestorsKendra Adams,
617-503-7028Kendra.adams@ariad.comorFor MediaLiza Heapes,
617-620-4888Liza.heapes@ariad.com
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Sep 2023 to Sep 2024